Why the study?
Assessing congestion is challenging and requires a multiparametric approach, leading investigators to evaluate whether coronary sinus diameter can predict mortality in rapid fluid unloading.
Does coronary sinus diameter measured by echocardiography predict all-cause mortality in patients with end-stage chronic kidney disease undergoing hemodialysis?
Does coronary sinus diameter measured by echocardiography predict all-cause mortality in patients with end-stage chronic kidney disease undergoing hemodialysis?
A persistently dilated coronary sinus (>9 mm) after hemodialysis accurately identifies residual congestion and strongly predicts 1-year mortality in patients with end-stage chronic kidney disease.
Persistently dilated CS after hemodialysis signals residual congestion and higher 1-year mortality; leaves open whether routine CS assessment improves risk stratification in ESKD.
Congestion predicts a poor prognosis, but its assessment is challenging in clinical practice and requires a multiparametric approach. We investigated if the coronary sinus (CS) diameter can predict mortality in a human model of rapid fluid unloading. We measured by echocardiography the CS, and the inferior vena cava (IVC) for comparison, in 60 patients with end-stage chronic kidney disease (ESKD) immediately before and after hemodialysis (HD; age 76 [57–81] years, 40% female, left ventricular ejection fraction 57 [53–56]%). Patients were prospectively followed up for all-cause mortality. HD-induced decongestion decreased the maximum diameters of both CS and IVC (p ≤ 0.001 for all). The maximum diameter of the CS (CSmax) was as accurate as the IVC maximum diameter and collapsibility for the identification of congestion, defined as pre-hemodialysis status (AUROC CSmax = 0.902 vs IVC = 0.895, p = n.s.). A CSmax diameter after hemodialysis > 9 mm predicted all-cause mortality at 12 months (Log-rank Chi square = 11.49, p < 0.001). A persistently dilated CS after hemodialysis is a marker of residual congestion and predicts death at one year in high-risk ESKD patients.
No takes yet. Share an insight, caveat, or question.
Barchitta et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: